Roche Group Member Genentech's Gazyva Shows Results In Lupus Nephritis Study, Could Delay Kidney Disease
Roche Group Member Genentech's Gazyva Shows Results In Lupus Nephritis Study, Could Delay Kidney Disease
罗氏集团成员基因泰克的Gazyva在狼疮性肾炎研究中显示出结果，可能延迟肾脏疾病。
Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated with Gazyva plus standard therapy (mycophenolate mofetil and glucocorticoids) achieved a complete renal response (CRR) at 76 weeks compared to those treated with standard therapy alone. Safety was in line with the well-characterized profile of Gazyva. No new safety signals were identified.
罗氏集团成员基因泰克（Roche Group）（SIX: RO, ROG, OTCQX:RHHBY）今天宣布，Gazyva（obinutuzumab）在进行中的第III期REGENCY研究中的上线结果积极，该研究针对患有活动性狼疮性肾炎的患者。在该研究中，接受Gazyva联合标准疗法（麦考酚酯酶和糖皮质激素）治疗的患者在76周时完成肾脏反应（CRR）的比例较接受单独标准疗法治疗的患者更高。安全性与Gazyva的良好特性一致。未发现新的安全信号。
"Gazyva achieved a robust complete renal response rate in lupus nephritis, which is associated with long-term...
"Gazyva在狼疮性肾炎中取得了...
登录免费看全文
登录/注册
资讯热榜
更新时间